Paris, Sept. 20 (Korea Bizwire) – Jeito Capital, a rapidly growing, new, independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at €534 million ($630 million), exceeding its original target of €500 million. Jeito I is the largest European fund dedicated to supporting companies in [...]
Paris, France, June 15 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has become a key investor as part of a $67 million Series B financing round in Alentis Therapeutics (Alentis). The Swiss biotech company, a spin-off of French Inserm with R&D in [...]
Paris, France, May 27 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has led an oversubscribed $92million Series C financing round in Pulmocide, a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases. Jeito led [...]
Paris, France, Dec. 14 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Series A financing in InnoSkel, a newly launched pioneering platform biotechnology company developing therapies for rare and life-threatening skeletal diseases. Jeito co-led the financing in a [...]
Paris, France, Nov. 13 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly experienced team of pharmaceutical and biotech experts in line with its investment criteria to provide [...]
Paris, France, Oct. 21 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has become a major investor in SparingVision, a French preclinical stage biotech company focused on gene therapy in ophthalmology. The €44.5 million financing round brought together new investors alongside Jeito including [...]
Paris, France, Sept. 14 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that it has co-led a $110 million Series A financing in Neogene Therapeutics, Inc. (“Neogene”), a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer. [...]